BioAtla reports Q3 EPS (27c), consensus (30c)

“We remain on track for completing a partnership transaction by year end.” said Jay Short, chairman, CEO and co-founder of BioAtla (BCAB). “In addition, we’ve achieved FDA alignment on our Phase 3 registrational Oz-V trial design, and we continue to be encouraged by our CAB T-cell engagers progress with the achievement of the recent CAB-Nectin4-TCE milestone and the promising data from CAB-EpCAM-TCE, or BA3182, recently presented at ESMO.”